Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Heres what we know and dont know: Most cases were described as mild and did not lead to stopping the drug Its not seen with semaglutide or tirzepatide it may be related to glucagon receptor activation, but this isnt confirmed The Phase 2 trial did note altered or enhanced skin sensation at lower rates, so it may not be entirely new just more apparent at scale It needs investigation across the remaining 7 Phase 3 trials reporting in 2026 Is it a dealbreaker
For others, theyre so severe that the medications need to be stopped
Berberine is unsafe for infants, so it should not be used when pregnant or breastfeeding
Always consult a licensed healthcare provider before making any decisions about weight management or metabolic health treatments
